🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Neuroprotective Effects of Melatonin on Neurotrophic, Apoptotic/Antiapoptotic and Inflammation Markers in the Rat Cerebrum and Cerebellum after Cranial Radiotherapy.

PMID: 41698670 · DOI: 10.1667/RADE-25-00237 · Radiation research, 2026 · Fatih Hacımustafaoğlu, Serhat Aras, Yalçın Erzurumlu, Burcu Çaykara Peran
📄 Abstract

This study aims to investigate the radioprotective effects of melatonin (MEL) against oxidative damage that may be caused by flattening filter (FF) and flattening filter-free (FFF) beam in the cerebrum and cerebellum of rat using various genetic markers. Forty female Wistar albino rats were randomly assigned to five groups. The control group received no intervention. The FF group received a single 16 Gy fraction at 600 MU/min. The FF+MEL group received the same FF protocol, preceded by melatonin (50 mg/kg, intraperitoneal) administered 15 min before irradiation. The FFF group received a single dose of 16 Gy at 2,400 MU/min. The FFF+MEL group received the same FFF protocol with melatonin administered as above. After treatment, cerebrum and cerebellum tissues were harvested, and mRNA expression levels of BDNF, CREB, BAX, BCL2 and IL6 were measured. Both FF and FFF radiotherapy treatments significantly increased BDNF, CREB, IL6, and BAX gene expression in cerebrum and cerebellum tissues, while decreasing BCL2 levels (P < 0.05). Melatonin treatment increased BDNF and CREB expression, significantly attenuated radiation-induced increases in IL6 and BAX, and partially reversed the decrease in BCL2 (P < 0.05). The increase in the BAX/BCL2 ratio after radiotherapy was significantly attenuated by melatonin treatment. Overall, FFF irradiation induced a stronger oxidative, inflammatory, and pro-apoptotic response than FF, whereas melatonin exhibited potent neuroprotective and anti-apoptotic effects. In conclusion, MEL demonstrates potential as a protective agent for healthy tissues during irradiations, owing to its antiapoptotic, anti-inflammatory, and neurotrophic properties.

Confidence: 0.17 · 8 полей извлечено
Идентификация (6 полей)
Target
Melatonin
0.95
Alt. target
MEL
0.95
Protein family
0.00
Functional class
0.00
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
0.00
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
Cerebrum and cerebellum tissues from rats were analyzed for mRNA expression of BDNF, CREB, BAX, BCL2, and IL6.
0.95
In vitro
0.00
In vivo
Forty female Wistar albino rats were randomly assigned to five groups: control, FF radiotherapy, FF+MEL, FFF radiotherapy, FFF+MEL. Melatonin (50 mg/kg, intraperitoneal) was administered 15 min before irradiation. Cerebrum and cerebellum tissues were harvested for gene expression analysis.
0.95
In silico
0.00
Genetic association
mRNA expression levels of BDNF, CREB, BAX, BCL2, and IL6 were measured in cerebrum and cerebellum tissues. Radiotherapy increased BDNF, CREB, IL6, BAX and decreased BCL2. Melatonin increased BDNF and CREB, attenuated IL6 and BAX increases, and partially reversed BCL2 decrease. BAX/BCL2 ratio increased after radiotherapy and was attenuated by melatonin.
0.95
Ex vivo
0.00
Animal model
Female Wistar albino rats
0.95
Diet/model
Cranial radiotherapy model using flattening filter (FF) and flattening filter-free (FFF) beams, with melatonin pretreatment.
0.95
Клиника (11 полей)
Drug
Melatonin
0.95
Indication
0.00
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
0.00